Finite collineation groups in projective spaces of one two and three dimensions

The account given in this thesis of the finite collineation groups in projective spaces of one, two and three dimensions is divided into two main sections. Section I indicates some of the methods available for determining the orders of the primitive groups in these spaces, with particular reference to the work done in one and two dimensions by H.F. Blichfeldt, and in three dimensions by G. Bagnera. Section II is an investigation of some of the primitive groups in three dimensions which are generated by biaxial homographies. This latter section has four main paragraphs; in paragraph II the groups generated by biaxial homographies which leave fixed a quadric are determined, and we are concerned with those groups which are isomorphic with symmetric groups in paragraph III; the methods used in these two paragraphs are my own. The group of order 11520 which leaves fixed the Klein 60 15, configuration is the subject of paragraph IV, the operations of this group and some of its subgroups are found by methods based on those used by J. Todd to determine a simple group of order 25920 in four dimensions. Similar methods are used in paragraph V to find the operations of a simple group of order 25920 leaving fixed a configuration of forty-five points and planes; the configuration has been described by G. Bagnera, but I can find no other account of the group in three dimensions.<p

Impact of a Prohibitive Versus Restrictive Tobacco Policy on Liver Transplant Candidate Outcomes

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/150602/1/lt25497_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/150602/2/lt25497.pd

Quality standards for the management of alcohol-related liver disease: consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group

Objective Alcohol-related liver disease (ALD) is the most common cause of liver-related ill health and liver-related deaths in the UK, and deaths from ALD have doubled in the last decade. The management of ALD requires treatment of both liver disease and alcohol use; this necessitates effective and constructive multidisciplinary working. To support this, we have developed quality standard recommendations for the management of ALD, based on evidence and consensus expert opinion, with the aim of improving patient care.Design A multidisciplinary group of experts from the British Association for the Study of the Liver and British Society of Gastroenterology ALD Special Interest Group developed the quality standards, with input from the British Liver Trust and patient representatives.Results The standards cover three broad themes: the recognition and diagnosis of people with ALD in primary care and the liver outpatient clinic; the management of acutely decompensated ALD including acute alcohol-related hepatitis and the posthospital care of people with advanced liver disease due to ALD. Draft quality standards were initially developed by smaller working groups and then an anonymous modified Delphi voting process was conducted by the entire group to assess the level of agreement with each statement. Statements were included when agreement was 85% or greater. Twenty-four quality standards were produced from this process which support best practice. From the final list of statements, a smaller number of auditable key performance indicators were selected to allow services to benchmark their practice and an audit tool provided.Conclusion It is hoped that services will review their practice against these recommendations and key performance indicators and institute service development where needed to improve the care of patients with ALD

Understanding alcohol-related liver disease patients' illness beliefs and views about their medicine

Alcohol is believed to be a factor in 80% of cases of liver cirrhosis in the UK and carries a poorer prognosis than other causes (McCarron & Welter 2012, Thompson et al 2008). Alcohol-related liver disease (ALD) also makes a major contribution to a rise in hospital admissions and mortality rate (Neame & Hammond 2005). As a chronic condition, patients with ALD are often required to take diuretics and laxatives for the rest of their lives. These medications require constant monitoring and titrating of effect, carrying substantial side effects while often their intended effect may not be readily apparent. 30 – 50% of all patients do not take their treatment as prescribed, leading to a significantly increased risk of morbidity and mortality (Horne et al 1999), and there is every reason to suspect that people with ALD are no exception